Seshu Tyagarajan is CTO at Candel Therapeutics, Inc. (CADL). They have made 6 open-market trades across 1 company since 2022, most recently 2026-08-17.
CIK 0001923794
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $25K since 2022, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CADL | 76,865 | $629K |
Shares reported on the most recent Form 4, priced at the 2026-08-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CADL | SELL · 10b5-1 | 2026-08-17 | 2026-08-19 | $12.00 | $84K | -0.2% | -17.4% | — |
| CADL | SELL · 10b5-1 | 2026-06-29 | 2026-07-01 | $10.02 | $70K | -1.6% | -0.2% | +8.6% |
| CADL | SELL · 10b5-1 | 2025-03-17 | 2025-03-20 | $8.82 | $552K | -33.3% | -46.0% | -41.1% |
| CADL | SELL | 2025-01-15 | 2025-01-17 | $7.23 | $207K | +2.1% | +39.6% | -33.0% |
| CADL | SELL | 2025-01-08 | 2025-01-10 | $8.22 | $239K | -13.1% | +6.8% | -41.3% |
| CADL | SELL | 2024-11-29 | 2024-12-03 | $4.56 | $186K | +45.2% | +93.3% | +70.1% |
| CADL | SELL | 2024-07-17 | 2024-07-19 | $6.47 | $192K | -1.3% | -12.6% | -2.3% |
| CADL | SELL | 2024-07-11 | 2024-07-15 | $5.97 | $159K | -1.5% | -20.4% | -9.2% |
| CADL | BUY | 2022-12-08 | 2022-12-12 | $1.88 | $25K | -34.7% | -27.5% | -40.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.